Mercury neuropathy …

Jonathan S Rutchik MD MPH

Peripheral Neuropathies

Updated 08.15.2023
Released 11.01.1999
Expires For CME 08.15.2026

Mercury neuropathy

Author: Jonathan S Rutchik MD MPH

See Contributor Disclosures

Editor: Louis H Weimer MD

Mercury neuropathy

In This Article

Quick Link

Introduction

Overview

Mercury neuropathy is a recognized sequela of occupational or environmental exposure to one of the various forms of the heavy metal. In this article, the author discusses common exposure sources, biological exposure indices, and clinical manifestations of mercury toxicity while focusing on mercury neuropathy for elemental, inorganic, and organic mercury. The author has updated this article to reflect the current literature regarding peripheral nervous system disease and this commonly encountered metal.

Key points

	• Peripheral neuropathy from mercury exposure most commonly involves distal latency sensory slowing for short-term exposures, followed by motor slowing for more long-term exposures.
	• Inorganic and elemental mercury exposures are more likely to cause peripheral nervous system complaints and findings.
	• Central nervous system effects are more common with organic mercury exposures.
	• Twenty-four-hour urine mercury best assesses exposures to inorganic or elemental mercury. Blood mercury is most appropriate for short-term exposures.

Historical note and terminology

Inorganic mercury is historically associated with environmental epidemics in Iraq and Japan, illness in occupational settings, and bizarre poisonings that have led to detective investigations.

Mercury has been known to cause illness in artists, gilders, gold refiners, and workers using metals in dyes, cosmetics, and unguents since Roman times. Later, occupational hazards of mining metallic mercury were associated with a slow death. Mercury and its salts were used as salves for syphilitics until the mid-20th century. Teething powders and antihelminthics are now rarely made with mercury (80; 85).

Today, dental amalgams, eye ointments, dermatological antiseptics, and hemorrhoidal sclerotics are still common medical sources of mercury. Calomel, a type of inorganic mercury salt also known as “sweet mercury,” was used in laxatives and teething powders, the latter leading to outbreaks of “pink disease” or acrodynia, a hypersensitivity syndrome to elemental mercury that can occur in children (85; 39). Occasional cases are still reported today.

Mercury is extracted from ore called cinnabar (HgS) by a roasting process. Elemental mercury, also called quicksilver or liquid silver, is a liquid at room temperature. Mercury exists in three oxidative states and also forms univalent (mercurous) and bivalent (mercuric) compounds. Mercuric chloride is readily dissolved, ionized, and absorbed and is more toxic than the less soluble mercurous chloride. Phenylic mercury compounds are less toxic than alkyl mercury compounds. Toxicity of these and other organic compounds have only been recognized in this century.

Elemental mercury is used in barometers, thermometers, and gauges. Mercuric salts are used in gold, silver, and bronze plating processes. Mercury is also found in electronic equipment, such as batteries, switches, rectifiers, compact fluorescent light bulbs, and mercury vapor lamps. Inorganic mercury is used in photography, antiseptics, tanning processes, embalming, felt manufacturing, and wood preservation methods.

Mercury poisoning in hat makers resulted from prolonged exposure to mercury vapors in poorly ventilated factories. Lewis Carroll’s Mad Hatter from the children’s tale Alice in Wonderland is literature’s most famous victim of mercury toxicity. A ban in the United States on using mercurous nitrate in the hat-making industry was finally instituted in 1941.

Exposure to elemental mercury vapor occurs in the chloralkali industry during chlorine manufacturing. Natural gas from certain sites has been reported to contain elemental mercury, and this exposure can occur in inspectors and maintenance or equipment workers at these sites. Metallic mercury is used in dental amalgams. Literature has discussed this as a possible low-level hazard in the dental workplace. In 1994, the Agency for Toxic Substances and Disease Registry (ATSDR) estimated 70,000 workers were exposed to mercury in the United States; 10% to 20% were estimated to experience intoxication. Some mercurochromes have been used as preservatives and antibacterials; thimerosal, which contains less than 2% mercury, has been suspected but not proven to affect autism rates.

Clinical manifestations

Presentation and course

Environmental sources. Because mercury is ubiquitous, exposure to mercury does not necessarily lead to illness. Mercury is present in water, air, and soil. The United States Environmental Protection Agency (EPA) has listed safe levels of mercury for humans in air, soil, and water.

The general population may experience exposure from dental amalgams or seafood. ATSDR has reported that very small mercury exposures are not necessarily harmful to one’s health, but active research is ongoing. Sensitive populations are identified as pregnant woman, children under 6 years of age, those with impaired renal function, and those with hypersensitive immune systems. ATSDR has also reported that chelation and removal of amalgams is not indicated in those without health effects from mercury.

Pyatha and colleagues also reported that patients exposed to mercury through dental amalgam fillings are at a six-fold increased risk for the development of Parkinson disease compared to nonexposed patients (60).

Santos-Sacramento and colleagues systematically reviewed mercury’s neurotoxic impact on individuals in the Amazon with mercury exposure within three river basins (Tapajos, Tocantins, and Madeira) (67). Their findings showed mercury body burden was two to 10 times higher than recommended with neurologic deficits noted in cognitive function, vision, motor function, somatosensory, and emotional deficits.

Exposures may also be experienced by religious groups who use mercurial agents in ceremonies. Exposure may occur to those using the agent as well as those who might inhale contaminated air nearby. Metallic mercury is sold in botanicas under the name azogue and is common in the Haitian and Hispanic communities. Inorganic mercury was found to be a component of a previously unrecognized source of exposure: skin care products in New York City (53). These products were found to be produced mainly in the Dominican Republic. A large study assessing urine mercury in 1840 adults in New York City was accomplished, and it uncovered 13 individuals with levels exceeding the New York State reportable level of 20 ug/L. All of these individuals were either Hispanic or African American and between the ages of 21 and 51. Ten of these women were born in the Dominican Republic. Whitening skin creams were confiscated, tested, and found to contain 0.62% mercury by weight. Blood mercury levels were assessed and found to be positively associated with elevated urine mercury. Seventeen different products were seized from stores and tested for mercury. Eight of these were skin-lightening or beauty creams; nine were made in the Dominican Republic, and seven listed mercury as a component of the cream.

A report from Taiwanese literature identified a 51-year-old male who was dispensed traditional medicine to treat a perianal fistula (87). After using hong-dan, he presented with perianal gangrene, fever, rash, and numbness, and later he presented with progressive weakness. EMG/NCV did, in fact, reveal a mixed axonal along with demyelinating features (reduced sensory amplitude, prolonged F waves). Hypokalemia, normocytic anemia, and elevated CRP were noted. AIDP was suspected, and despite plasmapheresis, his numbness and weakness worsened. A chelating agent, succimer (DMSA), was given, and high urine mercury and arsenic resulted. On day 27, the mixed axonal and demyelinating picture remained. Four years later, the patient had partial resolution of his symptoms, but NCV revealed nonresponse for peroneal motor and sural sensory studies. The authors wrote that hong-dan and tung oil are preparations banned due to lead content, but the paste remains compounded with unlicensed practitioners and may also contain significant mercury and arsenic.

A 4-year-old boy admitted to the hospital for rapidly progressing difficulty in walking had been treated for about 2 months with primarily ammoniated mercury ointment for itchy, macular lesions thought to be insect bites over his scalp and body. On examination, he was irritable but with an unremarkable physical examination. He did have pronounced weakness of the flexors and extensors of the feet and less of the legs, and his muscles of the upper extremities were slightly weak, but he had no atrophies or fasciculations. It was noted that he had no signs of acrodynia; however, with his irritability, polyneuropathy, albuminocytologic dissociation in the CSF, 9% eosinophils of the peripheral blood, and history of prolonged use of ammoniated mercury ointment, mercury intoxication was suspected. This was confirmed by a 24-hour urine mercury level of 0.3 mg/L. The patient was treated with dimercaprol (BAL) 3 mg per kg body weight four times a day, then twice daily. The patient showed progressive strength improvement, and when re-examined as an outpatient a year later, he walked normally and demonstrated no motor weakness. Achilles reflexes, however, were still absent. The authors concluded that pathogenesis was evidently a combination of chronic absorption and the individual’s hypersensitivity to inorganic mercury. The authors also noted that their patient did not display signs of acrodynia but did resemble a case of abortive acrodynia with mild polyneuritis, atypical extrapyramidal hyperkinesia, asynergia, eosinophilia, and albumin-cytologic dissociation in the CSF, after being treated with a mercury preparation rectally as an anthelmintic (61).

In 2010, twin 13-year-old sisters were admitted for generalized body pain, especially in the extremities and back, and they complained of headaches, chilling, and sweating (39). Noted was a 2-month history of pain in their legs, gradually causing them not to be able to walk to school. Anorexia, weakness, lethargy, excessive sweating, and salivation were also noted. Itchy rash on the body and extremities presented 2 weeks before hospital admission. On admission, the patients were irritable and depressed and had tachycardia without elevated blood pressure or body temperature. MRI of the brain and thighs and EMG/NCV testing were normal in both patients. Twenty-four-hour urine mercury concentration were measured and revealed toxic levels (50 and 70 ug/L). The mother later recalled using a compound that contained mercury to treat pediculosis 3 months before the onset of symptoms. The compound was purchased from an herbal shop and was applied locally on the scalps for 2 days. The twins were treated with D-penicillamine (DPCN) 20 ug/kg/d orally in four divided doses. They were additionally treated with gabapentin (300 ug) orally in three divided doses for pain. After 2 weeks of therapy, 24-hour urine mercury concentrations had fallen to 9 to 15 ug/L, and the patients were discharged. The authors reported that the sisters’ clinical presentation was compatible with acrodynia, characterized by dark pink discoloration and scaling of the hands and feet, weakness, pain, irritability, hypertension, tachycardia, peripheral neuropathy, recessive salivation, and sweating. The authors concluded that mercury poisoning should always be included in the differential diagnosis when patients present with bone or joint pain, skin rash erythema, and peripheral neuropathy.

In another pediatric case study, a 14-year-old boy was seen at a rheumatology clinic with severe back and extremity pain, weight loss, and weakness (41). Initial labs and MRI were all normal, but EMG showed mild neurogenic involvement on L2-S1. Clinical investigation discovered he had played with a bottle of mercury on a construction site 2 months prior. Follow-up showed blood mercury levels were significantly high, and he was treated with dimercaptosuccinic acid with reduced complaints over the following months (41).

A 54-year-old female with early onset dementia, epilepsy, and peripheral polyneuropathy was diagnosed with mercury intoxication in 2010, and she failed chelation therapy with 2,3-dimercaptopropane-1-sulfonate (DMPS) in 2013. EMG revealed chronic denervation in the tibialis anterior, but no follow-up studies were performed. Following a detailed patient history, it was found that she had been using a mercury-containing skin-lightening cream daily for 6 years. Treatment with 200 mg oral DMSA three times a day was initiated. Blood mercury levels fell from 13.3 to 5.2 ug/L, NSE levels fell from 31.4 to 20.5 ug/L, and urine mercury levels fell from 18.4 to 3.7 ug/L. Follow-up brain MRI showed unchanged brain lesions and one new lesion seen in the left temporo-occipital subcortical region. On discharge, however, memory function was improved qualitatively and quantitatively (90). The Environmental Protection Agency (USEPA) and U.S. Food and Drug Administration (FDA) “Advice About Eating Fish” states that eating fish while pregnant or breastfeeding can provide healthy benefits; however, it is important to avoid fish high in mercury, such as swordfish, king mackerel, marlin, and shark (81). Other fish associated with high mercury levels are tilefish from the Gulf of Mexico, Orange roughy, and Bigeye tuna.

A diet heavy in shellfish, fish, and marine mammals from mercury-contaminated waters may lead to high blood mercury levels. The largest and oldest fish will have the highest levels of mercury. The U.S. Food and Drug Administration (FDA) has estimated the amount of mercury in a normal adult diet and found it not to be harmful. Literature has described that this risk is likely underestimated (16).

Other food sources of mercury exposure have also been identified. NHANES data combined with that from the U.S. Department of Agriculture’s Food Intakes Converted to Retail Commodities Database (FICRCD) examined 49 different food and environmental metal exposure. Using results from blood and urinary biomarkers, researchers estimated that 4.5% of the variation of mercury among children and 10.5% among adults is explained by diet. A previously unrecognized association between rice consumption and mercury exposure was found (24). Latov and colleagues identified that environmental sources may play a role in idiopathic axonal and small fiber neuropathy (see below) (48).

Various forms of mercury poisoning. The various forms of mercury (organic mercury compounds, inorganic mercury salts, and elemental mercury) are all potentially neurotoxic and may produce different clinical pictures. They will be considered separately.

Organic mercury poisoning and neuropathy. Organic mercury is readily absorbed through the skin and gastrointestinal tract. Data concerning organic mercury (methylmercury) poisoning have come from accidental human exposures. Mercuric chloride is an inorganic compound used as an industrial catalyst. In the Japanese fishing village of Minamata, it was discharged into the sea for decades by an industrial plant and converted into methylmercury by microorganisms. It then entered the food chain and was concentrated in the bodies of fish and shellfish. These organisms served as staple items in the diet of the local population. It was observed that cats and seabirds, who also fed on the fish, were developing neurologic disease, leading to the identification of methylmercury as the toxin (45).

Paresthesias and sensory loss in stocking-glove distributions were noted in the distal extremities of Minamata Bay inhabitants. Muscle atrophy was also reported, and these symptoms appeared to have worsened over a 3- to 10-year period (79).

Another major outbreak arose in Iraq after grain treated with an ethyl mercury fungicide was used for baking bread (37; 08). This grain had originally been intended for planting. Paresthesias were also observed in these caes (29).

During chronic exposure to methylmercury, prominent central nervous system disease develops, including visual field constriction, ataxia, dysarthria, hearing loss, tremor, and cognitive impairment. One of the earliest complaints in many patients is distal paresthesia (77), which progresses proximally and may involve the tongue. This and ataxia are probably related to selective toxic effects on the neurons of the dorsal root and trigeminal sensory ganglia. Excretion of methylmercury is first order in humans, and its half-life has been estimated to be roughly 70 days (22). There may be a long latency period between the time of exposure and the onset of neurologic symptoms; the reason for this latency is not clear (56).

Dimethylmercury, a “supertoxin,” is lethal in doses of only a few drops, even if the exposure is brief. Exposure may occur via inhalation or transdermal absorption; typical disposable latex gloves do not protect against permeation. A tragic case of dimethylmercury poisoning occurred in 1996. A 48-year-old chemistry professor accidentally spilled drops of dimethyl mercury from her pipette onto the back of her latex glove. After a latent period of over 5 months, she developed a progressive cerebellar syndrome with gait ataxia, dysmetria, and scanning speech. Subsequently, she suffered progressive visual and hearing loss, paresthesias in the limbs, and encephalopathy. Despite 3 months of aggressive treatment, including chelation therapy with oral DMSA and exchange transfusion, she was left in a condition resembling a persistent vegetative state; life support was withdrawn in accordance with previous wishes (56).

A link between thimerosal, an ethyl mercury-containing preservative used in vaccines, and autistic spectrum disorders has been suggested. There are no compelling studies to date, however, to substantiate these claims (57). In 2002, The World Health Organization advisory committee deemed it safe to continue to use thimerosal in vaccines (74). Nevertheless, thimerosal-containing vaccines are no longer used in the United States, with the exception of influenza vaccines. Ingestion of a large dose of thimerosal in an adult led to multisystemic toxicities, including peripheral neuropathy, with subsequent recovery (59).

Le Quesne and associates evaluated 19 patients with organic mercury poisoning, four of whom were severe, and none demonstrated peripheral electrodiagnostic abnormalities, suggesting a CNS etiology for their complaints (49). Von Burg and Rustam evaluated Iraqis with poisonings and found no abnormalities. However, they did discover that patients responded better to neostigmine than placebo (82; 62).

In 1981, a brief report described increased mercury vapor released into the breath by chewing (75). Patients with silver-mercury amalgam fillings were compared to patients without these fillings. The authors raised the question that biotransformation might occur, and low levels of ingested or inhaled mercury might be converted into more toxic methylmercury. Despite the lack of direct evidence for this biotransformation, the role of dental amalgam in the production of neurologic disease has repeatedly arisen. Cases have included peripheral neuropathy, dementing disorders, motor neuron diseases, and chronic fatigue syndrome. No published studies have ever been able to link amalgam fillings to neurologic disease, and no trial has ever demonstrated a benefit from removing fillings. After an intensive investigation and review of the evidence, the Public Health Service concluded in 1993 that dental amalgams did not pose a serious health risk (44). A study of 1663 middle-aged men found no detectable association between amalgam exposure and peripheral neuropathy (40). Shapiro, however, found 30% of dentists with raised tissue levels of mercury had electrodiagnostic evidence of reduced mean sural and median motor conduction velocities compared to dentists with normal tissue mercury levels, consistent with subclinical neuropathy (70). For these reasons, it must be concluded that, at present, there is no evidence to link amalgam fillings to specific neurologic disease. Furthermore, the removal process generates mercury vapor, raising mercury blood concentrations substantially before eventual decline (22).

A paper by Latov and colleagues, evaluating blood levels of mercury by mass spectrophotometry in patients with idiopathic axonal and small fiber neuropathy, found an increased incidence of elevated blood levels, which were suspected to be from ingestion of methylmercury in seafood (48). Although cause or contribution to these neuropathies was not concluded, certainly more studies are warranted.

Inorganic mercury poisoning and neuropathy. It is difficult to separate the effects of elemental mercury from those of mercuric salts because most cases arise from occupational exposure to both forms (11). It is probable that inorganic mercury, because of its greater water solubility, is best absorbed through the gut; it produces prominent systemic as well as nervous system effects. Elemental mercury, with greater lipid solubility, may produce nervous system disease with almost no systemic disease.

Mercury salts are used in a number of industrial processes. The major route of absorption of these mercury salts is by way of the gastrointestinal tract. Mercuric sulfate has been found in traditional Chinese herbal medications, which have been implicated in cases of mercury neuropathy (21). Gastrointestinal symptoms and a nephrotic syndrome may be prominent systemic features, especially in acute poisoning.

Inorganic mercury is used in the chloralkali industry. Peripheral nerve dysfunction, often motor more than sensory, was noted in the cases summarized. Albers and colleagues reported 138 chloralkali plant workers with long-term exposure to inorganic mercury vapor who were found to have elevated urine mercury levels, reduced sensation on quantitative testing, prolonged distal motor latencies, reduced sensory evoked response amplitudes, and increased likelihood of abnormal needle EMG findings. Subjects exposed to mercury for 20 to 35 years who had urine mercury levels greater than 0.6 mg/L demonstrated significantly less strength, poorer coordination, more severe tremor, more impaired sensation, and higher prevalence of Babinski and snout reflexes than controls. Subjects with polyneuropathy had higher peak levels of mercury than healthy subjects. Factory workers exposed to elemental mercury vapor with elevated urine mercury concentrations had prolonged motor and sensory ulnar distal latencies. Slowing of the median motor nerve conduction velocity was found to correlate with both increased levels of mercury in blood and urine and increased numbers of neurologic symptoms. Sensory deficits were found with short-term exposure to mercury vapor, whereas motor nerve impairment occurred with longer periods of exposure (05; 04). Motor nerves appeared to be more affected than sensory nerves in a study by Singer in 1987 that assessed 16 workers with inorganic mercury exposure. Median motor NCV slowing correlated with mercury blood and urine as well as an increased prevalence of neurologic symptoms (71).

In another study by Andersen and coworkers, chloralkali workers exposed to inorganic mercury vapor for an average of 12.3 years revealed a higher prevalence of reduced distal sensation, postural tremor, and impaired coordination than controls revealed (07).

Barber reported two employees of a chloralkali plant who had findings suggestive of amyotrophic lateral sclerosis (09). Signs, symptoms, and laboratory findings returned to normal 3 months after withdrawal from exposure.

Adams and associates reported a 54-year-old man with a brief but intense exposure to mercury vapor, which led to a syndrome resembling amyotrophic lateral sclerosis that resolved as urinary mercury levels fell (02). Ross reported that prolonged application of an ammoniated ointment to the skin was a cause of motor polyneuropathy with cerebrospinal fluid findings suggestive of Guillain-Barré syndrome.

Warkany and Hubbard reported the association of acrodynia and symmetrical flaccid paralysis with mercury toxicity (84).

Chloralkali workers who were exposed to inorganic mercury for an average of 7.9 years and had ceased working in that environment an average of 12.3 years before the study were found to have both median sensory nerve conduction velocities and amplitude of the sural nerve associated with measures of cumulative mercury exposure (07; 26). A study reviewing the relationship between exposure-related indices and neurologic and neurophysiologic effects in workers previously exposed to mercury vapor revealed that, of 298 dentists with long-term exposure to mercury amalgam vapor evaluated for peripheral neuropathy, 30% had polyneuropathies (70). Another paper reported that a dentist apparently had an unelicitable sensory superficial peroneal nerve action potential that returned to normal following penicillamine treatment (36).

Industrial workers with long-term mercury exposure were found to have performance decrements in neuromuscular functions that were reversible and correlated with blood and urine mercury levels (11).

A 2019 Norwegian literature review of dentists and dental personnel exposed to mercury in the occupational setting was done to evaluate the relevance between mercury exposure in the dental industry and idiopathic disturbances in motor functions, cognitive skills, and affective reactions, as well as dose-response relationships. This study looked at dentists, dental assistants, and dental students from various countries. In multiple studies reviewed, neuropsychological effects in attention, psychomotor speed, cognitive flexibility, visual memory, short-term memory, visual memory, and visuomotor coordination were noted. In another study of neuropsychological performances in low-level mercury-exposed female dental workers, results showed that even chronic subtoxic levels of inorganic mercury can cause mild modifications in short-term nonverbal recall and generally increased distress, psychoticism, and anxiety. These researchers concluded that dental workers exposed to chronic, low levels of metallic mercury resulted in significant neurologic and sensory symptoms. Of these, memory loss was noted as potentially the most important.

Elemental mercury poisoning. Acute inhalation of elemental mercury vapor can cause irritation to the upper respiratory tract causing acute pneumonitis, bronchitis, and bronchiolitis and is commonly mistaken for viral infection if not properly diagnosed (13).

Chronic inhalation of elemental mercury may cause adverse health effects if exposure is above the minimal risk level of 0.3 μg/m3 (03). Clinical presentations are subtle and typically considered insignificant. Complaints include fatigue, general weakness, lack of appetite, diarrhea, lack of sleep, change in mood, and tremor, which has been called “micromercurialism” (35). The tremor is described as fine and rapid, worsens with activity and emotional excitement, and resembles the tremor seen in patients with hyperthyroidism. The tremor frequency, however, is faster and differs from the characteristic resting pill-rolling seen in Parkinson patients (32).

Elemental mercury is absorbed poorly from the gastrointestinal tract; swallowing mercury is not known to be harmful. Metallic mercury is volatile at room temperature. A saturated atmosphere of mercury vapor contains 18 mg of Hg per cubic meter at 24 degrees Celsius. Friberg and Nordberg have demonstrated that chronic Hg exposure to levels above 0.1 mg/m³ in air is associated with the development of toxicity (35). This level is of particular significance because small quantities of metallic mercury may remain hidden for long periods in poorly ventilated areas. Because of its greater lipid solubility, toxicity often manifests first by central nervous system symptoms of fatigue associated with weight loss, anorexia, and gastrointestinal dysfunction. With higher exposure, personality and behavioral changes, insomnia, and hyperexcitability develop, often associated with a coarse facial, head, and limb tremor. A few cases of predominantly peripheral nervous system involvement associated with exposure to organic and elemental mercury have been recorded (61; 76; 86). Elemental mercury exposure from broken school barometers led to symptoms and signs of mercury toxicity in three teenagers; all three had secondary hypertension, and two of the three developed peripheral neuropathy and CNS involvement (43).

A review of several studies that included more than 3000 workers chronically exposed to mercury between the years 1950 and 2015 found that urine mercury levels from less than 50 ug/L to more than 200 ug/L showed increased frequency in tremor, impaired coordination, and abnormal reflexes on physical examination and reduced neurobehavioral tests of tremor, manual dexterity, and motor speed. The data suggest that response thresholds of urine mercury levels of about 275 ug/L for physical exam findings and about 20 ug/L for neurobehavioral outcomes (34).

Seventeen thermometer factory workers with no neurologic complaints had high urine and blood mercury levels but no symptoms; 14 had subclinical neuropathy, mainly distal and axonal neuropathy (89).

Levine and associates, in 1982, studied right ulnar nerve NCVs in factory workers with elemental mercury exposure (50). Prolonged motor and sensory distal latencies were correlative with increasing urine mercury levels.

Albers and colleagues evaluated 386 chloralkali workers with 20 to 35 years of elemental mercury exposure and uncovered prolonged sensory and motor distal latencies in those workers whose biological monitoring revealed urine mercury concentrations above 600 ug/L (06). EMG was also performed and was noted to show an increased prevalence of abnormal electrical activity.

Authors in the United States reported that a patient developed gait ataxia, diplopia, and vomiting 1 year after self-injection of elemental mercury during a cultural practice (52). He was found to have an indurated plaque on his right shoulder along with cranial neuropathies. Urine mercury was elevated. CSF revealed pleocytosis. After excision of the skin lesion, a reservoir of mercury, and chelation, he experienced mild improvement.

In 2013, Turkish authors reported 179 children were exposed to elemental mercury in schools in two different provinces of Turkey (18). Children took the mercury home and invited others to play with it. Some boiled the material, heated it, and even tasted it. Median exposure duration was 5 minutes, but some played for 24 hours. Fifty-one percent were asymptomatic, and 44% had a normal neurologic examination. Thirty percent had headaches, and 5.5% had symptoms of peripheral neuropathy with normal NCV and EMG. MRIs of the brains were normal. Duration of exposure was correlated with elevated urine mercury. Pupillary dilatation was noted as the most common exam finding. After 6 months, peripheral neuropathy symptoms resolved.

In 2015, Korean workers involved in a fluorescent lamp factory demolition project developed acute symptoms of mercury poisoning from mercury vapor (25). Eighteen of 21 workers participating in the demolition project developed symptoms, with 10 of 18 having persistent symptoms 18 months postexposure. Initial symptoms included skin rash, pruritus, myalgia, and sleep disturbance. Late-onset symptoms included fatigue, insomnia, and anxiety disorder. Three workers developed jerky movement, and two had swan neck deformity of the fingers. Mean blood mercury levels were 5.88 ug/L, and the adjusted urinary mercury levels were 13.48 ug/L - creatinine. The lack of improvement by several of the workers was thought to be the result of mercury being captured by the central nervous system. Unfortunately, for workers whose condition did not improve, their symptoms were predicted to become chronic.

Prognosis and complications

The prognosis for recovery from peripheral nervous system involvement is good, although deficits may persist in severe cases (21). CNS injury is usually permanent. Recovery of elemental mercury exposure and peripheral neuropathy was reviewed in detail by Calabrese and colleagues, who reported that there is significant uncertainly due to a lack of animal and human data for this issue (17).

Biological basis

Etiology and pathogenesis

The cause of disease may be an occupational, accidental, or suicidal exposure to mercury compounds. Industrial uses of mercury, including the manufacture of batteries, latex paint, urethane, and polyvinyl chloride; fossil-fuel plants, incinerators, and municipal sewage systems as well as industrial discharge into rivers and streams may all lead to environmental pollution with mercury. Indeed, everyone is exposed to mercury in some form, whether from a source listed above or from thimerosal- or phenylmercuric nitrate-containing pharmaceuticals, fish consumption, or dental amalgams. Due to its accumulation in the food chain, chronic exposure to methylmercury via consumption of fish and sea mammals is still a major concern for human health, especially developmental exposure that may lead to neurologic alterations, including cognitive and motor dysfunctions (19). Thus, it is common to be able to detect mercury in blood, hair, and nails of normal people (44). Specific sources of accidental mercury exposure are quicksilver used in ethno-religious ceremonies common in some Hispanic and Caribbean communities, paint fumes from phenylmercuric acetate-containing interior latex paint, broken mercury-containing barometers or thermometers, Chinese herbal-ball preparations (27; 21), mercurial skin-lightening soaps and creams, spilled elemental mercury from pressure gauges, mercurials in gold recovery methods, ammoniated mercury ointments for the treatment of eczema or psoriasis (38; 58), teething compounds (85), diaper powders, and broken fluorescent light bulbs.

Following the outbreak of methylmercury intoxication in Minamata, extensive pathologic reports were published. These primarily involved the central nervous system, where prominent atrophy and degeneration of the cerebellar and calcarine cortex are seen (77). In the peripheral nerves of humans, axonal degeneration in the sural nerve and lumbar dorsal roots has been demonstrated (77). In experimental animal studies, the major pathologic change appears to be axonal degeneration without segmental demyelination. This has been shown in the L6 dorsal roots of rats but not in the ventral roots. The rate of axonal degeneration in the sural nerve is the same at mid-thigh and ankle level; therefore, the dorsal root ganglion cell is thought to be the primary site of action in the peripheral nervous system (54). Somjen and colleagues have demonstrated in rats that methylmercury administration resulted reduced the compound action potential evoked in dorsal roots, whereas the ventral root action potential was virtually normal (72; 73). This physiologic action was correlated with the finding that the major site of uptake of radioactive 203 Hg methylmercury in the peripheral nervous system was the spinal dorsal root ganglia. In a rat model study, both methylmercury and mercury vapor produced selective degeneration of dorsal root ganglia and dorsal nerve roots (68; 69). The number of autopsy cases for Minamata disease has risen (28). In one case autopsy, the dorsal roots and sural nerve showed endoneurial fibrosis, loss of nerve fibers, and the presence of Büngner bands. The spinal cord showed Wallerian degeneration of the fasciculus gracilis (Goll tract) with relative preservation of neurons in the sensory ganglia. These findings support the contention that peripheral nerve degeneration exists in patients with Minamata due to toxic injury from methylmercury.

Thus, in humans and animals, it appears that the major pathologic effect of methylmercury is on the dorsal root ganglion cells. In experimental models, it was found that the sensory neurons in the spinal ganglia and granule cells in the cerebellum were most vulnerable to mercury poisoning. Ultrastructural studies indicated that vacuolar degeneration of the neurons was mainly associated with inorganic mercury intoxication, whereas the coagulative type of degeneration was found mostly in organic mercury poisoning. Degenerative changes in the nerve fibers were also observed. Based on the biochemical, physiological, and pathological findings on mercury intoxication, a working hypothesis on the pathogenetic mechanism of mercury on the nervous system is proposed (20). No similar data are available for inorganic or metallic mercury poisoning. Because of the different chemical properties and clinical manifestations, these latter compounds likely exert their action at a different site. Three major mechanisms have been identified as critical in methylmercury-induced cell damage, including (i) disruption of calcium homeostasis, (ii) induction of oxidative stress via overproduction of reactive oxygen species or reduction of antioxidative defenses, and (iii) interactions with sulfhydryl groups (19).

Differential diagnosis

Mercury intoxication usually involves the subacute onset of mood and intellectual changes, followed by tremor and other signs suggestive of spinocerebellar involvement. There may also be significant constriction of visual fields. Differential diagnosis would include subacute cerebellar degeneration as a paraneoplastic syndrome, multiple sclerosis, and the cerebellar form of Creutzfeldt-Jakob disease. In long-term or chronic exposure with a slowly progressive course, mercury intoxication might resemble spinocerebellar degeneration. There is one case report of mercury intoxication initially mimicking amyotrophic lateral sclerosis (but with subsequent recovery) after a brief, intense exposure to elemental mercury (02). Mercury toxicity may resemble renal artery stenosis or rarer causes of secondary hypertension, such as pheochromocytoma or neurofibroma, because mercury binds and inactivates S-adenosylmethionine, an enzyme involved in catecholamine catabolism (10).

When considering whether a patient’s neuropathy arises from occupational or environmental toxicity, one should consider the following algorithm.

Table 1. Algorithm for Clinical Assessment of Neurotoxic Disease

	• Begin the evaluation by noting the chief complaint or complaints. Consider when they began and how they relate to an exposure.
	• Take a thorough medical history that includes an occupational and environmental history to consider all sources of exposure to all possible agents. List details of all jobs and job tasks within the jobs and what symptoms and medical problems began when.
	• Consider a review of systems and how eating, bowel movements, sexual activity, sleep, and emotional status varied during exposure incidents.
	• List medical complaints on a timeline and relate each to known exposure dates, duration, and intensity. Consider other occupational, environmental, and drug exposures. Include vitamin supplements, hobbies, and traditional practices.
	• Include birth history, pregnancy, and extensive family history to uncover any genetic or congenital diseases.
	• Consider how symptoms change as they relate to exposures. How often do flare-ups occur? Are the symptoms persistent or do they improve?
	• Do colleagues or coworkers have similar complaints?
	• List all potential sources of exposure: from where, what form, and how they are used.
	• Obtain Material Safety Data Sheets and scientific data on each unfamiliar chemical agent.
	• Perform neurologic examination. A general medical examination is important, including an assessment of the autonomic system, hair, teeth, nails, skin color, and lymph system. Are any objective neurologic signs or other systemic findings noted?
	• Arrange for appropriate confirmatory neurophysiological, neuropsychological, and imaging tests.
	• Arrange for serum and biological monitoring when appropriate
	• Review regulatory information for mercury. What have OSHA, EPA, NIOSH, American Conference of Governmental Industrial Hygienists (ACGIH), and other international organizations published as a safe level?
	• Consider contacting an industrial hygienist for air and water sampling, if relevant.
	• Consider removal from exposure.
	• Consider whether exposure and medical problems may be consistent chronologically. First, did the exposure precede the complaint or dysfunction?
	• Exclude all other common causes of the diagnosis. Are the findings consistent with a primary neurologic or other medical condition? Are the findings explained by other historical or familial factors? Other exposures, illnesses, or stressors?
	• Search the literature for epidemiologic and case studies and series that describe an association between exposure and dysfunction.
	• Is dose and duration of exposure consistent with the described dysfunction? Focus on details of the literature.
	• What is the proposed mechanism for this exposure-induced dysfunction?
	• Estimate functional status and medical treatment options and consultation necessary for support.
	• Reevaluate by examination and neurologic and neuropsychological tests. Do the results remain consistent?
(33; 63)

Diagnostic workup

The diagnosis of mercury intoxication depends on the demonstration of an appropriate neurologic syndrome in the context of exposure of mercury or mercury compounds. If there are symptoms or signs of neuropathy, nerve conduction studies and needle electromyography should be performed. Typical findings are that of a sensorimotor axonal neuropathy; myokymia may sometimes be encountered. EMG needle examination may show chronic neurogenic changes, which are most notable in the intrinsic foot muscles (51). In the case of methylmercury intoxication, circumstantial evidence may be the only form available because the compound has such a high affinity for the nervous system that neurologic disease may be present in the absence of elevated urine mercury levels.

In the case of inorganic or metallic mercury intoxication, this can usually be confirmed by measurement of 24-hour urinary mercury excretion using flameless atomic absorption spectrophotometry or mass spectroscopy. Mercury is excreted slowly from the body. The biological half-life for mercury excretion differs depending on its form; ethyl mercury is estimated to have a half-life of 20 days, whereas inorganic divalent mercury, mercury vapor, and methylmercury are estimated to have half-lives of 40, 60, and 70 days, respectively (22). At the Mayo Clinic trace metal laboratory, the mean level for nonexposed individuals is 5 mcg per 24-hour period. Occupationally exposed individuals may excrete 25 to 30 mcg per 24-hour period; levels above 50 per 24 hours raise the question of toxicity related to mercury exposure. It is important to note that blood mercury may be best to assess organic mercury, whereas urine mercury best assesses inorganic or elemental mercury exposures.

Biological testing of serum and urine to assess absorbed dose may be compared to values published for these data. These data suggest that urine or blood levels are associated with the health effects of mercury exposure.

Table 2. ATSDR Biological Exposure Indices (BEIs)

Compound	Urine	Blood	Expired Air	Other
Mercury, inorganic	Mercury: start of shift, 35 µg/g Cr	Mercury: end of shift at end of work week, 15 µg/L

When occupational exposure occurs, industrial hygiene data may be helpful. The Occupational Safety and Health Administration (OSHA), the National Institute of Safety and Health (NIOSH), and the American Congress of Governmental Industrial Hygienists (ACGIH) are useful resources from which to compare the workers’ inhalation exposure. Estimating dose and duration of exposure and level of protection afforded by personal protective equipment is emphasized. Government and professional organizations publish exposure limits for workers using various chemicals. Physicians may use this information to compare with industrial hygiene data (30; 46; 32; 63; 64; 65; 66).

Table 3. Published Limits for Mercury Exposure

Compound	OSHA PEL TWA: ppm (mg/m3)	NIOSH REL TWA: ppm (mg/m3), IDLH	ACGIH ppm (mg/m3) TLV, STEL
Mercury, inorganic	C 0.1 mg/m3 (construction)	0.05 mg/m3, C 0.01 mg/m3, 10 mg/m3	0.025 mg/m3
Mercury, organic	0.01 mg/m3, C 0.04 mg/m3	0.01 mg/m3, ST 0.03 mg/m3, 10 mg/m3	0.01 mg/m3, 0.03 mg/m3
Abbreviations: OSHA - Occupational Safety and Health Association; NIOSH - National Institute of Occupational Safety and Health; ACGIH - American Congress of Governmental Industrial Hygienists; TWA - time-weighted average; TLV - threshold limit value; PEL - permissible exposure limit; REL - recommended exposure limit; ppm - parts per million; STEL - short-term exposure limit; C - ceiling, should never be exceeded (30; 31; 32; 12; 46; 63; 64; 65; 66).

Management

Supportive measures are discussed in Peripheral neuropathies: supportive measures and rehabilitation.

Treatment for mercury neurotoxicity includes chelating agents British anti-Lewisite, meso-2,3-dimercaptosuccinic acid (DMSA), D-penicillamine (DPCN), and oral 2,3 dimercapto 1 propanesulfonate (DMPS). These have been used in cases where dramatic neurotoxicity is confirmed from mercury exposure.

Animal experiments support a role for chelation in acute exposure cases and should be instigated promptly in such cases. Efficacy declines or disappears as the time interval between metal exposure and the onset of chelation increases (42). Side effects include hypersensitivity, renal effects, and aplastic anemia. Hemodialysis may also be used in cases where renal function is compromised. L-cysteine may significantly improve the ability of hemodialysis to remove circulating mercury. DMSA taken orally has been approved by the U.S. Federal Drug Administration (FDA) for the treatment of mercury poisoning (55), and it is the only chelator that has been approved by the FDA for treating mercury poisoning in children (39).

DMSA and DMPS are found to be less toxic and more efficient than British anti-Lewisite in the treatment of heavy metal poisoning and are available in capsules for oral use (01). These agents also do not redistribute mercury to the brain or accelerate excretion, but a decrease in morbidity and mortality is not clearly established for cases of chronic intoxication (42).

With inorganic mercury intoxication, for those who do not respond quickly to removal from the source of the exposure (31), chelation with oral DMPS has been dramatically helpful in individual and case series. Bradberry and colleagues reported reversal of neurologic damage with a 5-day course of DMPS chelation in a jeweler who presented with a 1-year progressive neurologic syndrome after 5 years of exposure to mercury vapor (14).

Chelation may be appropriate for patients with inorganic mercury intoxication who do not respond quickly to removal from the source of the exposure (31). Chelation is rarely accomplished unless toxicity is present from acute occupational exposure that is confirmed by an occupational and environmental medicine physician or toxicologist.

There are practitioners in many communities who perform chelation routinely on patients with vague symptoms, but the literature has not supported this treatment. Chelation was successful in treating one patient who attempted suicide with mercuric chloride (15; 83).

References

01: Aaseth J, Sjaug MA, Cao Y, Andersen O. Chelation in metal intoxication—Principles and paradigms. J Trace Elem Med Biol 2015;31:260-6. PMID 25457281
02: Adams CR, Ziegler DK, Lin JT. Mercury intoxication simulating amyotrophic lateral sclerosis. JAMA 1983;250(5):642-3. PMID 6864963
03: Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for mercury. Atlanta: U.S. Dept of Health and Human Services, Public Health Service Agency for Toxic Substances and Disease Registry, 1999.
04: Albers J, Bromberg MB. Chemically induced toxic neuropathy. In: Rosenberg NL, editor. Occupational and environmental neurology. Boston: Butterworth-Heinemann, 1995:175-234.
05: Albers JW, Cavender GD, Levine SP, Langolf GD. Asymptomatic sensorimotor polyneuropathy in workers exposed to elemental mercury. Neurology 1982;32(10):1168-74. PMID 6289189
06: Albers JW, Kallenbach LR, Fine LJ, et al. Neurological abnormalities associated with remote occupational elemental mercury exposure. Ann Neurol 1988;24(5):651-9. PMID 2849369
07: Andersen A, Ellingsen DG, Morland T, Kjuus H. A neurological and neurophysiological study of chloralkali workers previously exposed to mercury vapour. Acta Neurol Scand 1993;88(6):427-33. PMID 8116345
08: Bakir F, Damluji SF, Amin-Zaki L, et al. Methylmercury poisoning in Iraq. Science 1973;181(96):230-41. PMID 4719063
09: Barber TE. Inorganic mercury intoxication reminiscent of amyotrophic lateral sclerosis. J Occup Med 1978;20(10):667-9. PMID 722351
10: Beck C, Krafchik B, Traubici J, Jacobson S. Mercury intoxication: it still exists. Pediatr Dermatol 2004;21(3):254-9. PMID 15165207
11: Berlin M. Mercury. In: Friberg L, editor. Handbook of the toxicology of metals. Amsterdam: Elsevier, 1979:503-30.
12: Bleeker ML. Clinical presentations of selected neurotoxic compounds. In: Bleeker ML, Hansen JA, editors. Occupational neurology and clinical neurotoxicology. Baltimore: Williams & Wilkins, 1994:207-34.
13: Bluhm RE, Bobbitt RG, Welch LW, et al. Elemental mercury vapor toxicity, treatment, and prognosis after acute, intensive exposure in chloralkali workers. Part I. History, neuropsychological findings and chelator effects. Hum Exp Toxicol 1992;11(3):201-10. PMID 1352115
14: Bradberry SM, Sheehan TM, Barraclough CR, Vale JA. DMPS can reverse the features of severe mercury vapor induced neurological damage. Clin Toxicol 2009;47(9):894-8. PMID 19852623
15: Brodkin E, Copes R, Mattman A, Kennedy J, Kling R, Yassi A. Lead and mercury exposures: interpretation and action. CMAJ 2007;176(1):59-63. PMID 17200393
16: Budtz-Jorgensen E, Grandjean P, Weihe P. Separation of risks and benefits of seafood intake. Environ Health Perspect 2007;115(3):323-7. PMID 17431478
17: Calabrese EJ, Iavicoli I, Calabrese V, Cory-Slechta DA, Giordano J. Elemental mercury neurotoxicity and clinical recovery of function: a review of ﬁndings, and implications for occupational health. Environ Res 2018;163:134-8. PMID 29438899
18: Carman KB, Tutkin E, Yilmaz H, et al. Acute mercury poisoning among children in two provinces of Turkey. Eur J Pediatr 2013;172(6):821-7. PMID 23411638
19: Ceccatelli S, Daré E, Moors M. Methylmercury-induced neurotoxicity and apoptosis. Chem Biol Interact 2010;188(2):301-8. PMID 20399200
20: Chang LW. The neurotoxicology and pathology of organomercury, organolead, and organotin. J Toxicol Sci 1990;15 Suppl 4:125-51. PMID 2100318
21: Chu CC, Huang CC, Ryu SJ, Wu TN. Chronic inorganic mercury induced peripheral neuropathy. Acta Neurol Scand 1998;98(6):461-5. PMID 9875628
22: Clarkson TW, Magos L, Myers GJ. The toxicology of mercury: current exposures and clinical manifestations. N Engl J Med 2003;349(18):1731-7. PMID 14585942
23: Davis LE, Kornfeld M, Mooney HS, et al. Methylmercury poisoning: long-term clinical, radiological, toxicological, and pathological studies of an affected family. Ann Neurol 1994;35(6):680-8. PMID 8210224
24: Davis MA, Gilbert-Diamond D, Karagas MR, et al. A dietary-wide association study (SWAS) of environmental metal exposure in US children and adults. PLoS One 2014;9(9):e104768. PMID 25198543
25: Do SY, Lee CG, Kim JY, et al. Cases of acute mercury poisoning by mercury vapor exposure during the demolition of a fluorescent lamp factory. Ann Occ Environ Med 2017;29:19. PMID 28649389
26: Ellingsen DG, Morland T, Andersen A, Kjuus H. Relation between exposure related indices and neurological and neurophysiological effects in workers previously exposed to mercury vapour. Br J Ind Med 1993;50(8):736-44. PMID 8398861
27: Espinoza EO, Mann MJ, Bleasdell B. Arsenic and mercury in traditional Chinese herbal balls. N Engl J Med 1995;333(12):803-4. PMID 7643901
28: Eto K, Tokunaga H, Nagashima K, Takeuchi T. An autopsy case of minamata disease (methylmercury poisoning)--pathological viewpoints of peripheral nerves. Toxicol Pathol 2002;30(6):714-22. PMID 12512873
29: Evans HL, Garman RH, Weiss B. Methylmercury: Exposure duration and regional distribution as determined from neurotoxicity in nonhuman primates. Toxicol Appl Pharmacol 1977;41(1):15-33. PMID 408941
30: Feldman RG. Effect of toxins and physical agents on the nervous system. In: Bradley WG, editor. Neurology in clinical practice. Boston: Butterworth-Heinemann, 1991:1185-207.
31: Feldman RG. The recognition and differentiation of neurotoxic and non-neurotoxic syndromes. In: Chang LW, Slikker W, eds. Neurotoxicology: approaches and methods. San Diego: Academic Press, 1995:689-94.
32: Feldman RG. Occupational and environmental neurotoxicology. Philadelphia: Lippincott-Raven, 1998.
33: Feldman RG, White RF. Role of the neurologist in hazard identification and risk assessment. Environ Health Perspect 1996;104 Suppl 2:227-37. PMID 9182031
34: Fields CA, Borak J, Louis ED. Mercury-induced and sensory neurotoxicity: systemic review of workers currently exposed to mercury vapor. Crit Rev Toxicol 2017;47(10):815-48. PMID 28718354
35: Friberg L, Nordberg GF. Inorganic mercury-relation between exposure and effects. In: Friberg L, Vostal J, editors. Mercury in the environment. Cleveland: CRC, 1972:113-39.
36: Iyer K, Goodgold J, Eberstein A, Berg P. Mercury poisoning in a dentist. Arch Neurol 1976;33(11):788-90. PMID 985159
37: Kantarjian AD. A syndrome clinically resembling amyotrophic lateral sclerosis following chronic mercurialism. Neurology 1961;11:639-44. PMID 13751207
38: Kern F, Roberts N, Ostlere L, Langtry J, Staughton RC. Ammoniated mercury ointment as a cause of peripheral neuropathy. Dermatologica 1991;183(4):280-2. PMID 1667099
39: Khodashenas E, Aelami M, Balali-Mood M. Mercury poisoning in two 13-year-old twin sisters. J Res Med Sci 2015;20(3):308-11. PMID 26109979
40: Kingman A, Albers JW, Arezzo JC, Garabrant DH, Michalek JE. Amalgam exposure and neurological function. Neurotoxicology 2005;26(2):241-55. PMID 15713345
41: Kisaarslan AP, Sozeri B, Bastug F, et al. Elemental mercury intoxication in 7 patients admitted to a pediatric rheumatology clinic. Turk J Pediatr 2019;61(5):786-90. PMID 32105014
42: Kosnett M. The role of chelation in the treatment of arsenic and mercury poisoning. J Med Toxicol 2013;9(4):347-54. PMID 24178900
43: Koyun M, Akman S, Guven AG. Mercury intoxication resulting from school barometers in three unrelated adolescents. Eur J Pediatr 2004;163(3):131-4. PMID 14722761
44: Kulig K. A tragic reminder about organic mercury. N Engl J Med 1998;338(23):1692-4. PMID 9614264
45: Kurland LT, Faro SN, Siedler H. Minamata disease: the outbreak of a neurologic disorder in Minamata, Japan, and its relationship to the ingestion of seafood contaminated by mercuric compounds. World Neurol 1960;1:370-91. PMID 13755288
46: LaDou J. Approach to the diagnosis of the occupational illness. In: LaDou J, editor. Occupational and environmental medicine, 2nd ed. New York, NY: McGraw-Hill, 1997:6-23.
47: Lapham LW, Cernichiari E, Cox C, et al. An analysis of autopsy brain tissue from infants prenatally exposed to methylmercury. Neurotoxicology 1995;16(4):689-704. PMID 8714873
48: Latov N, Kumar G, Vo ML, et al. Elevated blood mercury levels in idiopathic axonal neuropathy. JAMA Neurol 2015;72(4):474-5. PMID 25867721
49: Le Quesne PM, Damluji SF, Rustam H. Electrophysiologic studies of peripheral nerves in patients with organic mercury poisoning. J Neurol Neurosurg Psychiatry 1974;37:333-9. PMID 4364276
50: Levine SP, Cavender GD, Langolf GD, Albers JW. Elemental mercury exposure: peripheral neurotoxicity. Br J Ind Med 1982;39(2):136-9. PMID 6279139
51: Little AA, Albers JW. Clinical description of toxic neuropathies. Handb Clin Neurol 2015;131(3):253-96. PMID 26563794
52: Malkani R, Weinstein JM, Kumar N, Victor TA, Bernstein L. Ataxia and cranial neuropathies from subcutaneous injected elemental mercury. Clin Toxicol (Phila) 2011;49(4):334-6. PMID 21563911
53: McKelvey W, Jeffery N, Clark N, Kass D, Parsons PJ. Population-based inorganic mercury biomonitoring and the identification of skin care products as a source of exposure in New York City. Environ Health Perspect 2011;119(2):203-9. PMID 20923743
54: Miyakawa T, Deshimaru M, Sumiyoshi S, et al. Experimental organic mercury poisoning--pathological changes in peripheral nerves. Acta Neuropathol 1970;15(1):45-55. PMID 4190670
55: Mutter J, Yeter D. Kawasaki’s disease, acrodynia, and mercury. Curr Med Chem 2008;15(28):3000-10. PMID 19075648
56: Nierenberg DW, Nordgren RE, Chang MB, et al. Delayed cerebellar disease and death after accidental exposure to dimethylmercury. N Engl J Med 1998;338(23):1672-6. PMID 9614258
57: Parker SK, Schwartz B, Todd J, Pickering LK. Thimerosal-containing vaccines and autistic spectrum disorder: a critical review of published original data. Pediatrics 2004;114(3):793-804. PMID 15342856
58: Pelclova D, Lukas E, Urban P, et al. Mercury intoxication from skin ointment containing mercuric ammonium chloride. Int Arch Occup Environ Health 2002;75:S54-9. PMID 12397411
59: Pfab R, Muckter H, Roider G, Zilker T. Clinical course of severe poisoning with thimerosal. J Toxicol Clin Toxicol 1996;34(4):453-60. PMID 8699562
60: Pyatha S, Kim H, Lee D, Kim K. Association between heavy metal exposure and Parkinson’s disease: a review of the mechanisms related to oxidativ stress. Antioxidants 2022;11(2467):1-18. PMID 36552676
61: Ross AT. Mercuric polyneuropathy with albuminocytologic dissociation and eosinophilia. JAMA 1964;188:830-1. PMID 14132545
62: Rustam H, Von Burg R, Amin-Zaki L, El Hassani S. Evidence of neuromuscular disorder in methylmercury poisoning. Arch Envirol Health 1975;30(4):190-5. PMID 1091217
63: Rutchik JS. Toxic Neuropathy. www.Emedicine.com. Internet text. Updated 2007.
64: Rutchik JS. Occupational medicine physician’s guide to neuropathy in the workplace, part I. J Occup Environ Med 2009a;51(3):390-3. PMID 19276716
65: Rutchik JS. Occupational medicine physician’s guide to neuropathy in the workplace, part 2: electromyography and cryptogenic and toxic neuropathy. J Occup Environ Med 2009b;51(5):622-5. PMID 19423992
66: Rutchik JS. Occupational medicine physician’s guide to neuropathy in the workplace, part 3: case presentation. J Occup Environ Med 2009c;51(7):861-2. PMID 19528836
67: Santos-Sacramento L, Arrifano GP, Lopes-Araújo A, et al. Human neurotoxicity of mercury in the Amazon: a scoping review with insights and critical considerations. Ecotoxicol Environ Saf 2021;208:111686. PMID 33396018
68: Schionning JD, Eide R, Ernst E, Danscher G, Moller-Madsen B. The effect of selenium on the localization of autometallographic mercury in dorsal root ganglia of rats. Histochem J 1997;29(3):183-91. PMID 9472380
69: Schionning JD, Larsen JO, Eide R. A stereological study of dorsal root ganglion cells and nerve root fibers from rats exposed to mercury vapor. Acta Neuropathol 1998;96(2):185-90. PMID 9705135
70: Shapiro IM, Cornblath DR, Sumner AJ, et al. Neurophysiological and neuropsychological function in mercury-exposed dentists. Lancet 1982;1(8282):1147-50. PMID 6122938
71: Singer R, Valciukas JA, Rosenman KD. Peripheral neurotoxicity in workers exposed to inorganic mercury compounds. Arch Environ Health 1987;42(4):181-4. PMID 2821932
72: Somjen GG, Herman SP, Klein R. Electrophysiology of methyl mercury poisoning. J Pharmacol Exp Ther 1973a;186(3):579-92. PMID 4728337
73: Somjen GG, Herman SP, Klein R, et al. The uptake of methyl mercury (203Hg) in different tissues related to its neurotoxic effects. J Pharmacol Exp Ther 1973b;187(3):602-11. PMID 4770401
74: Strategic Advisory Group of Experts. Vaccines and biologicals: recommendations from the Strategic Advisory Group of Experts. Wkly Epidemiol Rec 2002;77:305-11. PMID 12298104
75: Svare CW, Peterson LC, Reinhardt JW, et al. The effect of dental amalgams on mercury levels in expired air. J Dent Res 1981;60:1668-71. PMID 6943160
76: Swaiman KF, Flagler DG. Penicillamine therapy of the Guillain-Barré syndrome caused by mercury poisoning. Neurology 1971;21:456-7.
77: Takeuchi T. Neuropathology of Minamata disease in Kumamoto: especially at the chronic stage. In: Roizin L, Shiraki H, Grcevic N, editors. Neurotoxicology. New York: Raven Press, 1977:235-46.
78: Takeuchi T, Eto K. Pathology and pathogenesis of Minamata disease. In: Tsubaki T, Irukayama K, editors. Minamata disease: methyl mercury poisoning in Minamata and Nigata, Japan. New York: Elsevier, 1977:103-41.
79: Tamashiro H, Arakaki M, Akagi H, Futatsuka M, Roth LH. Mortality and survival for Minamata disease. Int J Epidemiol 1985;14(4):582-8. PMID 4086144
80: Torres AD, Rai AN, Hardiek ML. Mercury intoxication and arterial hypertension: report of two patients and review of the literature. Pediatrics 2000;105(3):E34. PMID 10699136
81: US Food and Drug Administration and US Environmental Protection Agency 2020. Advice about eating fish: for women who are or might become pregnant, breastfeeding mothers, and young children. Available at: https://www.epa.gov/fish-tech/epa-fda-advisory-mercury-fish-and-shellfish#draft. Accessed February 2020.
82: Von Burg R, Rustam H. Electrophysiological investigations of methylmercury intoxication in humans. Evaluation of peripheral nerve by conduction velocity and electromyography. Electroencephalogr Clin Neurophysiol 1974;37(4):381-92. PMID 4136710
83: Wang EE, Mahajan N, Wills B, Leikin J. Successful treatment of potentially fatal heavy metal poisonings. J Emerg Med 2007;32(3):289-94. PMID 17394994
84: Warkany J, Hubbard DM. Acrodynia and mercury. J Pediatr 1953;42(3):365-86. PMID 13035637
85: Weinstein M, Bernstein S. Pink ladies: mercury poisoning in twin girls. CMAJ 2003;168(2):201. PMID 12538551
86: Windebank AJ, Dyck PJ. Metal neuropathy. In: Dyck PJ, Thomas PK, Lambert EH, Bunge R, editors. Peripheral neuropathy. Philadelphia: W.B. Saunders, 1986:2133-61.
87: Wu ML, Deng JF, Lin KP, Tsai WJ. Lead, mercury, and arsenic poisoning due to topical use of traditional Chinese medicines. Am J Med 2013;126(5):451-4. PMID 23582936
88: Yoshida Y, Kamitsuchibashi H, Hamada R, Kuwano Y, Mishima I, Igata A. Truncal hypesthesia in patients with Minamata disease. Intern Med 1992;31(2):204-7. PMID 1600268
89: Zampollo A, Baruffini A, Cirla AM, Pisati G, Zedda S. Subclinical inorganic mercury neuropathy: neurophysiological investigations in 17 occupationally exposed subjects. Ital J Neurol Sci 1987;8(3):249-54. PMID 3623876
90: Zellner T, Zellner N, Felgenhauer N, Eyer F. Dementia, epilepsy and polyneuropathy in a mercury-exposed patient: investigations, identification of an obscure source and treatment. BMJ Case Rep 2016;2016. PMID 27793866

Contributors

All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.

Author

Jonathan S Rutchik MD MPH

Dr. Rutchik of the University of California at San Francisco has no relevant financial relationships to disclose.
See Profile

Editor

Louis H Weimer MD

Dr. Weimer of Columbia University has no relevant financial relationships to disclose.
See Profile

Former Authors

Tony J Windebank MD (original author) and Robert W Pratt MD

Patient Profile

Age range of presentation: 0 month to 65+ years
Sex preponderance: male=female
Heredity: none
Population groups selectively affected: none selectively affected
Occupation groups selectively affected: none selectively affected

ICD & OMIM codes

ICD-9: Toxic effect of mercury and its compounds: 985.0

Poisoning by heavy metal anti-infectives: 961.2

Polyneuropathy due to other toxic agents: 357.7

Accidental poisoning by mercury and its compounds and fumes: E866.1

Heavy metal anti-infectives causing adverse effects in therapeutic use: E931.2
ICD-10: Toxic effects of mercury and its compounds: T56.1

Assault by other specified chemicals and noxious substances: X89.09

Polyneuropathy due to other toxic agents: G62.2

Accidental poisoning by mercury and its compounds and fumes: X49.09

Other specified systemic anti-infectives and antiparasitics: Y41.8

This is an article preview.
Start a Free Account
to access the full version.

Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660

Support: service@medlink.com

Editor: editor@medlink.com

ISSN: 2831-9125

Mercury neuropathy

Associated Disorders

Minamata disease
Myokymia

Differential Diagnosis

subacute cerebellar degeneration as a paraneoplastic syndrome
multiple sclerosis
cerebellar form of Creutzfeldt-Jakob disease
spinocerebellar degeneration
amyotrophic lateral sclerosis
- renal artery stenosis
- secondary hypertension
- pheochromocytoma
- neurofibroma
- glucose dysmetabolism

Also Relevant

Chelation therapy
Metal neurotoxicity
Toxic peripheral neuropathies

Mercury neuropathy …

Mercury neuropathy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Table 1. Algorithm for Clinical Assessment of Neurotoxic Disease

Diagnostic workup

Table 2. ATSDR Biological Exposure Indices (BEIs)

Table 3. Published Limits for Mercury Exposure

Management

Special considerations

Pregnancy

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview.
Start a Free Account
to access the full version.

Questions or Comment?

Also in This Category

Neuropathies associated with cytomegalovirus infection

Clinical evaluation of peripheral neuropathies

Hypothyroidism

Monoclonal gammopathy of neurologic significance

Chronic inflammatory demyelinating polyradiculoneuropathy

Amyotrophic lateral sclerosis

Amiodarone neuropathy

Autoimmune autonomic neuropathy

Mercury neuropathy

Introduction

Overview

Key points

Historical note and terminology

Clinical manifestations

Presentation and course

Prognosis and complications

Biological basis

Etiology and pathogenesis

Epidemiology

Prevention

Differential diagnosis

Table 1. Algorithm for Clinical Assessment of Neurotoxic Disease

Diagnostic workup

Table 2. ATSDR Biological Exposure Indices (BEIs)

Table 3. Published Limits for Mercury Exposure

Management

Special considerations

Pregnancy

References

Contributors

Author

Editor

Former Authors

Patient Profile

ICD & OMIM codes

This is an article preview. Start a Free Account to access the full version.

Questions or Comment?

Also in This Category

Neuropathies associated with cytomegalovirus infection

Clinical evaluation of peripheral neuropathies

Hypothyroidism

Monoclonal gammopathy of neurologic significance

Chronic inflammatory demyelinating polyradiculoneuropathy

Amyotrophic lateral sclerosis

Amiodarone neuropathy

Autoimmune autonomic neuropathy

This is an article preview.
Start a Free Account
to access the full version.